Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Public ClinicalTrials.gov record NCT02218489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease
Study identification
- NCT ID
- NCT02218489
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Interventions
- KPI-121 Drug
- Vehicle Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Nov 30, 2015
- Completion
- May 31, 2016
- Last update posted
- Jan 10, 2021
2014 – 2016
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB School of Optometry | Birmingham | Alabama | 35294-0010 | — |
| Sall Research Medical Center | Artesia | California | 90701 | — |
| North Valley Eye Medical Group | Mission Hills | California | 91345 | — |
| Wolstan & Goldberg Eye Associates | Torrance | California | 90505 | — |
| Tauber Eye Center | Kansas City | Missouri | 64111 | — |
| South Shore Eye Center, LLP | Wantagh | New York | 11793 | — |
| Abrams Eye Center | Cleveland | Ohio | 44115 | — |
| Virginia Eye Consultants | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02218489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2021 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02218489 live on ClinicalTrials.gov.